An autologous NK cell therapy product that composed 50-90% of activated NK and NKT cells, produced using a unique cell cultivation technology.
Who needs MYJ1633?
MYJ1633 holds promise for treatment in cancer, autoimmune disease and anti-aging. Find out more clinical results and testimonials conducted by ImmunisBio groups over the years.
Years in the Industry
Centres Worldwide
Patients Experienced
up to Dec 2021
Latest News
Let’s Discuss Your Personalized Treatment
Please fill out this confidential form and we will contact you promptly.